

Literatur/Literature

- [1] Deutsche Gesellschaft für Palliativmedizin e.V. (2016). *Zum Umgang mit Off-Label-Use in der Palliativmedizin*.
- [2] European Medicines Agency (2017). *10-year Report to the European Commission – General report on the experience acquired as a result of the application of the Pediatric Regulation*.
- [3] European Medicines Agency (2010). *Report on the survey of all pediatric uses of medical products in Europe*.
- [4] Dornelles AD, Calegari LH, de Souza L, Ebone P, Tonelli TS & Carvalho CG (2019). *The Unlicensed and Off-Label Prescription of Medications in General Paediatric Ward: An Observational Study*. *Curr Pediatr Rev*. 15, 1. doi: 10.2174/1573396314666181113101506.
- [5] Park MS (2018). *Regulatory innovation for expansion of indications and pediatric drug development*. *Transl Clin Pharmacol*. 26, 4. doi: 10.12793/tcp.2018.26.4.155.
- [6] Official Journal of the European Union (2007). *Regulation (EC) No 1901/2006 of the European Parliament and of the Council*.
- [7] European Commission (2017). *State of Pediatric Medicines in the EU – 10 years of the EU Pediatric Regulation*.
- [8] Tefera YG, Gebresillassie BM, Mekuria AB, Abebe TB, Erku DA, Seid N & Beshir HB (2017). *Off-Label Drug Use In Hospitalized Children: A Prospective Observational Study At Gondar University Referral Hospital*. *Value in Health* 20, 9.
- [9] <https://www.kinderformularium.nl/> (Stand: 25.02.2020)
- [10] <https://www.rcpch.ac.uk/resources> (Stand: 25.02.2020)
- [11] <https://www.kispi.uzh.ch/de> (Stand: 25.02.2020)
- [12] <http://www.drugbase.de/de/> [Stand: 25.02.2020]